AGL 6.39 Decreased By ▼ -0.06 (-0.93%)
ANL 9.65 Increased By ▲ 0.15 (1.58%)
AVN 76.95 Increased By ▲ 2.00 (2.67%)
BOP 5.41 Increased By ▲ 0.06 (1.12%)
CNERGY 4.91 Increased By ▲ 0.11 (2.29%)
EFERT 77.50 Decreased By ▼ -0.50 (-0.64%)
EPCL 55.30 Increased By ▲ 1.15 (2.12%)
FCCL 15.24 Increased By ▲ 0.24 (1.6%)
FFL 6.37 Increased By ▲ 0.17 (2.74%)
FLYNG 7.40 Increased By ▲ 0.39 (5.56%)
GGGL 10.35 Increased By ▲ 0.30 (2.99%)
GGL 16.36 Increased By ▲ 0.42 (2.63%)
GTECH 8.35 Increased By ▲ 0.50 (6.37%)
HUMNL 6.41 Increased By ▲ 0.14 (2.23%)
KEL 2.91 Increased By ▲ 0.08 (2.83%)
LOTCHEM 27.89 Increased By ▲ 0.24 (0.87%)
MLCF 28.00 Increased By ▲ 1.00 (3.7%)
OGDC 73.99 Increased By ▲ 0.64 (0.87%)
PAEL 15.51 Increased By ▲ 0.21 (1.37%)
PIBTL 5.21 Increased By ▲ 0.06 (1.17%)
PRL 16.65 Increased By ▲ 0.55 (3.42%)
SILK 1.07 Increased By ▲ 0.03 (2.88%)
TELE 10.61 Increased By ▲ 0.16 (1.53%)
TPL 7.84 Increased By ▲ 0.15 (1.95%)
TPLP 19.80 Increased By ▲ 0.58 (3.02%)
TREET 23.52 Increased By ▲ 0.77 (3.38%)
TRG 122.55 Increased By ▲ 6.65 (5.74%)
UNITY 22.90 Increased By ▲ 1.10 (5.05%)
WAVES 11.55 Increased By ▲ 0.40 (3.59%)
WTL 1.14 Increased By ▲ 0.02 (1.79%)
BR100 4,091 Increased By 51.6 (1.28%)
BR30 15,342 Increased By 358.7 (2.39%)
KSE100 40,931 Increased By 310.4 (0.76%)
KSE30 15,327 Increased By 114.1 (0.75%)

US Food and Drug Administration

US FDA extends review period for Biogen's Alzheimer's drug
Business & Finance

US FDA extends review period for Biogen's Alzheimer's drug

  • Our key takeaway is that if the FDA would have wanted to reject the drug, we would have heard the decision by now.
  • The road to getting a regulatory nod for the drug has been rocky, with the companies scrapping two studies of the therapy in March 2019, and reversing that decision a few months later.
Published 29 Jan, 2021 07:14pm